Abstract
This report describes a patient with small-cell lung cancer who was infected with both Mycobacterium tuberculosis and non-tuberculous mycobacterium. He received irinotecan plus cisplatin, with and without rifampin. Rifampin slightly reduced the conversion of irinotecan to 7-ethyl-10-hydroxycamptothecin (SN-38), as determined by pharmacokinetic analysis. Rifampin may influence the metabolism and toxicity of irinotecan to some extent. However, there are possibilities to control M. tuberculosis and Mycobacterium avium complex infections in patients with small-cell lung cancer by using rifampin in combination with irinotecan plus cisplatin.
MeSH terms
-
Antibiotics, Antitubercular / pharmacology
-
Antibiotics, Antitubercular / therapeutic use*
-
Antineoplastic Agents, Phytogenic / pharmacokinetics
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Camptothecin / analogs & derivatives*
-
Camptothecin / pharmacokinetics
-
Camptothecin / therapeutic use*
-
Carcinoma, Small Cell / complications
-
Carcinoma, Small Cell / drug therapy*
-
Drug Interactions
-
Glucuronates / pharmacokinetics
-
Humans
-
Irinotecan
-
Lung Neoplasms / complications
-
Lung Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Mycobacterium avium-intracellulare Infection / complications
-
Mycobacterium avium-intracellulare Infection / drug therapy
-
Rifampin / pharmacology
-
Rifampin / therapeutic use*
-
Tuberculosis, Pulmonary / complications
-
Tuberculosis, Pulmonary / drug therapy*
Substances
-
7-ethyl-10-hydroxycamptothecin beta-glucuronide
-
Antibiotics, Antitubercular
-
Antineoplastic Agents, Phytogenic
-
Glucuronates
-
Irinotecan
-
Rifampin
-
Camptothecin